Related Experiment Video

Updated: Aug 23, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.0K

Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the

Jacopo Uliano1,2, Eleonora Nicolò1,2, Carla Corvaja1,3

  • 1Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.

Expert Review of Clinical Pharmacology
|November 1, 2022
PubMed
Abstract

Insights

Triple-negative breast cancer (TNBC) treatment is evolving. Combining immune checkpoint inhibitors (ICIs) with other therapies shows promise, but overcoming resistance remains crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Breast Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited treatment options.
  • While anti-PD(L)1 immunotherapy shows potential in TNBC, monotherapy efficacy is often suboptimal, necessitating combination strategies.
  • Resistance to immune checkpoint inhibitors (ICIs) is a major obstacle, limiting their long-term benefit in TNBC patients.

Approach:

  • This review synthesizes the biological basis, current clinical data, and ongoing trials for combining immunotherapy with various agents in TNBC.
  • Investigates combinations of immunotherapy with novel immunotherapeutics, chemotherapy, targeted agents, and antibody-drug conjugates.
  • Focuses on strategies to overcome primary and secondary resistance to ICIs in the context of TNBC treatment.

Key Points:

  • Combination therapies, including ICIs plus chemotherapy, are increasingly integrated into TNBC treatment paradigms.
  • Exploiting synergistic effects between different therapeutic modalities is a key strategy to enhance ICI efficacy.
  • Identifying mechanisms of ICI resistance and developing predictive biomarkers are critical for patient selection and treatment optimization.

Conclusions:

  • The TNBC treatment landscape is dynamic, with ICIs now established, but significant unmet needs persist.
  • Novel combination strategies are essential to overcome resistance and extend the benefits of immunotherapy.
  • Future research should prioritize understanding ICI resistance and discovering robust biomarkers for personalized TNBC therapy.
Keywords:
PARP inhibitorsTNBCantibody-drug conjugateschemotherapycombinationimmune checkpoint inhibitorsimmunotherapysynergytargeted therapytriple-negative breast cancer

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
172